Europe rejects lecanemab, a controversial Alzheimer's drug

The European Medicines Agency (EMA) has rejected the approval of lecanemab, a new and controversial Alzheimer's drug, due to the risk of serious side effects. The drug, which targets amyloid protein in the brain, showed a modest 27% reduction in cognitive decline in clinical trials.

However, it also caused brain inflammation, hemorrhages, and even death in some patients. The EMA's decision aligns with the cautious approach taken by experts, who argue that the limited efficacy of lecanemab does not outweigh its potential risks.

The rejection raises concerns about the high costs and challenges associated with early detection and lifelong treatment of Alzheimer's. While the US FDA approved a similar drug, donanemab, last year, the EMA is currently evaluating its application.

Despite the disappointment surrounding lecanemab, researchers remain hopeful, emphasizing the need for new and safer treatments for Alzheimer's. With over 50 million people affected by the disease worldwide, finding effective solutions is crucial.